BackgroundCheck.run
Search For

Feng YeBrooklyn, NY

Feng Ye Phones & Addresses

Brooklyn, NY   

Bucyrus, OH   

227 Bay 7Th St, Brooklyn, NY 11228    718-3310623   

Work

Company: Ascend-newark chapter it committee

Education

Degree: High school graduate or higher
Get Report
Control this profile

Mentions for Feng Ye

Feng Ye resumes & CV records

Resumes

Feng Ye Photo 40

Feng Ye

Feng Ye Photo 41

Feng Ye

Feng Ye Photo 42

Feng Ye

Feng Ye Photo 43

Feng Ye

Location:
United States
Feng Ye Photo 44

Feng Ye

Location:
United States
Feng Ye Photo 45

Feng Ye - Fort Lee, NJ

Work:
Ascend-Newark Chapter IT Committee Jan 2012 to Jan 2013 Federal Home Loan Bank of New York - New York, NY May 2012 to Aug 2012
Credit Policy Intern Finance Co-op - New Brunswick, NJ May 2011 to Jan 2012 Columbia University - New York, NY Aug 2010 to Dec 2010
Administrative Assistant, Dept. of Microbiology
Feng Ye Photo 46

Feng Ye

Publications & IP owners

Us Patents

Substituted Aryl Sulfone Derivatives As Calcium Channel Blockers

US Patent:
8304434, Nov 6, 2012
Filed:
Sep 30, 2008
Appl. No.:
12/678454
Inventors:
Prasun K. Chakravarty - Edison NJ, US
Yanbing Ding - Richmond, CA
Joseph L. Duffy - Cranford NJ, US
Hassan Pajouhesh - West Vancouver, CA
Pengcheng Patrick Shao - Fanwood NJ, US
Sriram Tyagarajan - Edison NJ, US
Feng Ye - Scotch Plains NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/445
C07D 401/12
US Classification:
514318, 514252, 514255, 514256, 514303, 514321, 514323, 514326, 514330, 544238, 544300, 544353, 544405, 546121, 546139, 546156, 546194, 546202, 546208, 546210, 546226
Abstract:
A series of substituted aryl sulfone derivatives represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, calcium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, diabetic neuropathy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, sleep disorder, bipolar disorder and stroke, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.

Substituted-1-Phthalazinamines As Vr- 1 Antagonists

US Patent:
2009004, Feb 19, 2009
Filed:
Dec 18, 2006
Appl. No.:
12/086740
Inventors:
Pasun K. Chakravarty - Edison NJ, US
Pengcheng Patrick Shao - Fanwood NJ, US
Feng Ye - Scotch Plains NJ, US
International Classification:
A61K 31/397
C07D 401/02
C07D 471/04
C07D 211/58
A61K 31/497
A61K 31/4545
A61K 31/4535
A61K 31/4525
A61P 29/00
A61K 31/453
A61K 31/454
A61K 31/4468
C07D 405/02
C07D 413/02
C07D 409/02
US Classification:
51421018, 546223, 546194, 546214, 546208, 544336, 544408, 546209, 546172, 546207, 546211, 546121, 51425505, 514300, 514314, 514318, 514322, 514326, 514329
Abstract:
Substituted piperidine compounds represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.

Substituted Spirocyclic Amines Useful As Antidiabetic Compounds

US Patent:
2012004, Feb 16, 2012
Filed:
May 6, 2010
Appl. No.:
13/265146
Inventors:
Susan D. Aster - Teaneck NJ, US
Joseph L. Duffy - Cranford NJ, US
Patrick Shao - Fanwood NJ, US
Feng Ye - Scotch Plains NJ, US
International Classification:
A61K 31/438
A61K 31/506
A61P 3/10
A61P 25/22
A61P 3/06
A61P 3/04
A61P 3/00
A61P 25/24
C07D 471/10
A61P 5/48
US Classification:
514275, 546 16, 514278, 544230
Abstract:
Substituted spirocyclic amines of structural formula I are selective antagonists of the somatostatin sub-type receptor 5 (SSTR5) and are useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as Type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, metabolic syndrome, depression, and anxiety.

Substituted Aryl Sulfone Derivatives As Calcium Channel Blockers

US Patent:
2013004, Feb 14, 2013
Filed:
Sep 24, 2012
Appl. No.:
13/625508
Inventors:
Neuromed Pharmaceuticals Ltd. - Vancouver, CA
Joseph L. Duffy - Cranford NJ, US
Hassan Pajouhesh - West Vancouver, CA
Pencheng Patrick Shao - Fanwood NJ, US
Sriram Tyagarajan - Edison NJ, US
Feng Ye - Scotch Plains NJ, US
Assignee:
Neuromed Pharmaceuticals Ltd. - Vancouver
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07D 205/04
C07D 207/08
A61K 31/40
A61K 31/445
A61K 31/4545
A61P 25/20
A61K 31/454
A61K 31/498
A61K 31/519
A61K 31/4523
A61P 29/00
A61P 25/08
A61K 31/397
A61K 31/4709
US Classification:
51421018, 548953, 51421017, 548539, 514423, 514330, 514318, 514313, 514326, 514249, 514322, 5142593, 514300
Abstract:
A series of substituted aryl sulfone derivatives represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, calcium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, diabetic neuropathy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, sleep disorder, bipolar disorder and stroke, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.

Spiro Isoxazoline Compounds As Sstr5 Antagonists

US Patent:
2013004, Feb 14, 2013
Filed:
May 13, 2011
Appl. No.:
13/641767
Inventors:
Joseph L. Duffy - Cranford NJ, US
Jianming Bao - Princeton NJ, US
Debra L. Ondeyka - Fanwood NJ, US
Sriram Tyagarajan - Edison NJ, US
Patrick Shao - Fanwood NJ, US
Feng Ye - Scotch Plains NJ, US
Revathi Katipally - Monmouth Junction NJ, US
Paul E. Finke - Milltown NJ, US
Yi Zang - Princeton NJ, US
Michael A. Plotkin - Frenchtown NJ, US
F. Anthony Romero - Westfield NJ, US
Remond Moningka - Rahway NJ, US
Zahid Hussain - Dayton NJ, US
International Classification:
C07D 498/10
C07D 519/00
A61P 25/22
A61P 3/04
A61P 3/00
A61P 25/24
A61K 31/438
A61P 3/10
US Classification:
514278, 546 19
Abstract:
Substituted spirocyclic amines of structural formula (I) are selective antagonists of the somatostatin subtype receptor 5 (SSTR5) and are useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as Type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, Metabolic Syndrome, depression, and anxiety.

Fused Bicyclic Oxazolidinone Cetp Inhibitor

US Patent:
2013010, May 2, 2013
Filed:
Oct 25, 2012
Appl. No.:
13/660010
Inventors:
Pengcheng Patrick Shao - Fanwood NJ, US
Wanying Sun - Edison NJ, US
Revathi Reddy Katipally - Monmouth Junction NJ, US
Petr Vachal - Summit NJ, US
Feng Ye - Scotch Plains NJ, US
Jian Liu - Edison NJ, US
Deyou Sha - Yardey PA, US
International Classification:
A61K 31/424
A61K 31/4439
A61K 31/506
A61K 31/454
A61K 31/5355
A61K 31/519
A61P 9/10
A61P 3/06
A61K 31/437
A61K 31/444
A61K 31/455
A61K 31/714
C07D 498/04
A61K 31/4245
US Classification:
514 52, 548221, 514375, 5462717, 514338, 544331, 514275, 546198, 514321, 544 96, 5142288, 548144, 514364, 546116, 514302, 546256, 514333, 548143, 514356, 514249
Abstract:
Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.

Spiroxazolidinone Compounds

US Patent:
2013013, May 23, 2013
Filed:
Aug 12, 2011
Appl. No.:
13/810946
Inventors:
Joseph L. Duffy - Cranford NJ, US
Jianming Bao - Princeton NJ, US
Debra L. Ondeyka - Fanwood NJ, US
Sriram Tyagarajan - Edison NJ, US
Patrick Shao - Fanwood NJ, US
Feng Ye - Scotch Plains NJ, US
Revathi Katipally - Monmouth Junction NJ, US
Aaron Zwicker - New Haven CT, US
Edward C. Sherer - Manville NJ, US
Michael A. Plotkin - Frenchtown NJ, US
Remond Moningka - Rahway NJ, US
Zahid Hussain - Dayton NJ, US
Harold B. Wood - Westfield NJ, US
Feroze Ujjainwalla - Scotch Plains NJ, US
F. Anthony Romero - Redwood City CA, US
Paul E. Finke - Milltown NJ, US
Yi Zang - Princeton NJ, US
Weiguo Liu - Princeton NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07D 498/10
C07D 519/00
US Classification:
51421018, 546 19, 514278, 548216, 540543, 51421202, 514376, 544230, 514256
Abstract:
Substituted spirocyclic amines of structural formula (I) are selective antagonists of the somatostatin subtype receptor 5 (SSTR5) and are useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as Type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, Metabolic Syndrome, depression, and anxiety.

Monocyclic Isoxazolines As Inhibitors Of Cholesterol Ester Transfer Protein

US Patent:
2017021, Jul 27, 2017
Filed:
Jul 24, 2015
Appl. No.:
15/329284
Inventors:
Pengcheng Patrick Shao - Fanwood NJ, US
Feng Ye - Kenilworth NJ, US
Petr Vachal - Kenilworth NJ, US
Jayanth Thiruveliore Thatal - Bangalore, IN
- Rahway NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07D 261/04
A61K 31/397
A61K 31/42
A61K 31/444
A61K 31/4245
A61K 31/4439
C07D 413/14
A61K 45/06
C07D 413/10
Abstract:
Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, wherein D1, D2 and D3 are each N, CH, or substituted CH, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.

Isbn (Books And Publications)

Das Chinesische Gesetz Uber Partnerschaftsunternehmen: Im Vergleich Zum Deutschen Recht

Author:
Feng Ye
ISBN #:
3631388799

Possible Relatives

Dan Ye  Aaron H Ye  Diana X Ye  Ding C Ye  Dong Ye  Fei Ye  George Ye  Feng W Meng  Feng L Li  Feng Lin 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.